ANI PHARMACEUTICALS (ANIP) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$73.89
+2.7% on the day
-18.6% over 12 months
52-week range $70.19 – $95.38
Share price and insider trades
ANIP closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$15.1M
Insiders buying0
Insiders selling12
ANI PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 12 sold $15.1M of ANIP stock on the open market.
Get emailed when insiders cluster-buy stocks like ANIP
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ANIP insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $2.1M | 11 |
| Q2 2026 | — | 0 | $6.4M | 11 |
| Q1 2026 | — | 0 | $4.0M | 18 |
| Q4 2025 | — | 0 | $2.4M | 8 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.0×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 ANI PHARMACEUTICALS INC insiders reported open-market purchases totaling $0, while 12 insiders reported sales totaling $15.1M. 33 of 48 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ANIP earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 7, 2026 | +6.5% | Sold $273K | -8.3%S&P +0.6% | -6.7% |
| May 8, 2026 | +4.7% | Sold $39K | -6.2%S&P +1.1% | +4.0% |
| Feb 27, 2026 | +1.2% | Sold $1.3M | -2.5%S&P -0.4% | +1.0% |
| Jan 12, 2026 | -7.2% | Sold $134K | +7.9%S&P -0.0% | -6.8% |
| Nov 10, 2025 | -4.7% | Sold $36K | -2.1%S&P +1.8% | -7.2% |
| Nov 7, 2025 | -3.8% | Sold $36K | -1.4%S&P +1.7% | -7.8% |
| Sep 8, 2025 | +4.6% | None | +3.3%S&P +0.5% | -7.8% |
| Aug 8, 2025 | +3.2% | None | +23.0%S&P +0.6% | +14.8% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 30SEC | Stephen P. CareyCFO | Sell Plan | 2,850168,993 held (−2%) | $73.00 | $208K | +1.2% | — |
| Sep 16SEC | Nikhil LalwaniCEO, President | Sell Plan | 5,400339,089 held (−2%) | $71.00 | $383K | +4.1% | — |
| Sep 14SEC | Jeanne ThomaDirector | Sell Plan | 1,00026,762 held (−4%) | $71.53 | $72K | +3.3% | — |
| Sep 14SEC | Meredith CookGeneral Counsel | Sell Plan | 50073,924 held (−1%) | $70.79 | $35K | +4.4% | — |
| Sep 1SEC | Stephen P. CareyCFO | Sell Plan | 2,850171,843 held (−2%) | $72.80 | $207K | +1.5% | — |
| Aug 26SEC | Nikhil LalwaniCEO, President | Sell Plan | 5,400344,489 held (−2%) | $74.30 | $401K | -0.6% | — |
| Aug 13SEC | Meredith CookGeneral Counsel | Sell Plan | 50074,424 held (−1%) | $75.48 | $38K | -2.1% | — |
| Aug 11SEC | Ori GutwergSvp, Generics | Sell | 3,16275,534 held (−4%) | $77.00 | $243K | -4.0% | — |
| Jul 30SEC | Stephen P. CareyCFO | Sell Plan | 2,850174,693 held (−2%) | $81.36 | $232K | -9.2% | — |
| Jul 14SEC | Meredith CookGeneral Counsel | Sell Plan | 50077,390 held (−1%) | $81.84 | $41K | -9.7% | — |
| Jul 6SEC | Stephen P. CareyCFO | Sell Plan | 3,313177,543 held (−2%) | $86.00 | $285K | -14.1% | — |
| Jun 30SEC | Stephen P. CareyCFO | Sell Plan | 2,850177,543 held (−2%) | $84.12 | $240K | -12.2% | — |
| Jun 15SEC | Meredith CookGeneral Counsel | Sell Plan | 50077,890 held (−1%) | $82.03 | $41K | -9.9% | — |
| Jun 10SEC | Thomas HaugheyDirector | Sell Plan | 2,00038,878 held (−5%) | $80.88 | $162K | -8.6% | — |
| Jun 9SEC | Stephen P. CareyCFO | Sell Plan | 3,312180,393 held (−2%) | $80.00 | $265K | -7.6% | — |
| May 13SEC | Nikhil LalwaniCEO, President | Sell | 55,000349,889 held (−14%) | $77.57 | $4.3M | -4.7% | — |
| May 13SEC | Patrick D WalshDirector | Sell | 10,00038,432 held (−21%) | $80.63 | $806K | -8.4% | — |
| May 13SEC | Patrick D WalshDirector | Sell | 3,97348,432 held (−8%) | $80.75 | $321K | -8.5% | — |
| May 13SEC | Ori GutwergSvp, Generics | Sell | 2,77278,696 held (−3%) | $79.50 | $220K | -7.1% | — |
| May 13SEC | Meredith CookGeneral Counsel | Sell Plan | 50078,390 held (−1%) | $78.16 | $39K | -5.5% | — |
| May 13SEC | Thomas Andrew RowlandSvp, Head - Established Brands | Sell | 45938,271 held (−1%) | $79.21 | $36K | -6.7% | — |
| Apr 13SEC | Meredith CookGeneral Counsel | Sell Plan | 50078,890 held (−1%) | $77.95 | $39K | -5.2% | — |
| Mar 13SEC | Thomas Andrew RowlandSvp, Head - Established Brands | Sell | 4,77238,730 held (−11%) | $74.91 | $357K | -1.4% | — |
| Mar 13SEC | Christopher MutzHead Of Rare Disease | Sell Plan | 3,16291,309 held (−3%) | $71.64 | $227K | +3.1% | — |
| Mar 13SEC | Meredith CookGeneral Counsel | Sell Plan | 50079,390 held (−1%) | $72.62 | $36K | +1.7% | — |
| Mar 10SEC | Krista DavisSvp, Chief Hr Officer | Sell Plan | 5,08751,946 held (−9%) | $74.13 | $377K | -0.3% | — |
| Mar 10SEC | Christopher MutzHead Of Rare Disease | Sell Plan | 3,60294,471 held (−4%) | $74.18 | $267K | -0.4% | — |
| Mar 10SEC | Christopher MutzHead Of Rare Disease | Sell Plan | 2,121101,387 held (−2%) | $74.22 | $157K | -0.4% | — |
| Mar 10SEC | Krista DavisSvp, Chief Hr Officer | Sell Plan | 1,48557,033 held (−3%) | $75.00 | $111K | -1.5% | — |
| Mar 5SEC | Stephen P. CareyCFO | Sell | 4,000185,543 held (−2%) | $75.56 | $302K | -2.2% | — |
| Mar 5SEC | Stephen P. CareyCFO | Sell | 3,312189,543 held (−2%) | $75.42 | $250K | -2.0% | — |
| Mar 4SEC | Ori GutwergSvp, Generics | Sell | 2,06084,782 held (−2%) | $76.50 | $158K | -3.4% | — |
| Mar 4SEC | Christopher MutzHead Of Rare Disease | Sell Plan | 417103,508 held (−0%) | $74.00 | $31K | -0.1% | — |
| Mar 3SEC | Patrick D WalshDirector | Sell | 6,00052,405 held (−10%) | $74.23 | $445K | -0.5% | — |
| Feb 23SEC | Christopher MutzHead Of Rare Disease | Sell Plan | 5,32384,840 held (−6%) | $78.02 | $415K | -5.3% | — |
| Feb 23SEC | Krista DavisSvp, Chief Hr Officer | Sell Plan | 2,08450,993 held (−4%) | $77.53 | $162K | -4.7% | — |
| Feb 23SEC | Krista DavisSvp, Chief Hr Officer | Sell Plan | 1,73049,263 held (−3%) | $77.99 | $135K | -5.3% | — |
| Feb 17SEC | Christopher MutzHead Of Rare Disease | Sell Plan | 7,03292,566 held (−7%) | $76.55 | $538K | -3.5% | — |
| Feb 17SEC | Meredith CookGeneral Counsel | Sell Plan | 50069,329 held (−1%) | $76.80 | $38K | -3.8% | — |
| Jan 14SEC | Meredith CookGeneral Counsel | Sell Plan | 50074,374 held (−1%) | $84.33 | $42K | -12.4% | — |
| Dec 19SEC | Krista DavisSvp, Chief Hr Officer | Sell Plan | 1,62258,564 held (−3%) | $82.40 | $134K | -10.3% | — |
| Dec 12SEC | Meredith CookGeneral Counsel | Sell Plan | 40074,874 held (−1%) | $82.32 | $33K | -10.2% | — |
| Dec 9SEC | Renee P TannenbaumDirector | Sell | 1,80025,157 held (−7%) | $81.15 | $146K | -8.9% | — |
| Nov 17SEC | Patrick D WalshDirector | Sell | 8,64361,405 held (−12%) | $86.88 | $751K | -15.0% | — |
| Nov 14SEC | Chad GassertSvp - Corp. Dev. & Strategy | Sell | 14,642158,584 held (−8%) | $89.07 | $1.3M | -17.0% | — |
| Nov 14SEC | Meredith CookGeneral Counsel | Sell Plan | 40075,274 held (−1%) | $87.27 | $35K | -15.3% | — |
| Nov 14SEC | Chad GassertSvp - Corp. Dev. & Strategy | Sell | 94158,490 held (−0%) | $88.00 | $8K | -16.0% | — |
| Oct 14SEC | Meredith CookGeneral Counsel | Sell Plan | 40075,674 held (−1%) | $90.09 | $36K | -18.0% | — |
Insiders at ANI PHARMACEUTICALS INC
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Nikhil LalwaniCEO, President | — | $5.1M | Sep 16, 2026 | — |
| Patrick D WalshDirector | — | $2.3M | May 13, 2026 | — |
| Stephen P. CareyCFO | — | $2.0M | Sep 30, 2026 | — |
| Christopher MutzHead Of Rare Disease | — | $1.6M | Mar 13, 2026 | — |
| Chad GassertSvp - Corp. Dev. & Strategy | — | $1.3M | Nov 14, 2025 | — |
| Krista DavisSvp, Chief Hr Officer | — | $919K | Mar 10, 2026 | — |
| Ori GutwergSvp, Generics | — | $621K | Aug 11, 2026 | — |
| Meredith CookGeneral Counsel | — | $454K | Sep 14, 2026 | — |
| Thomas Andrew RowlandSvp, Head - Established Brands | — | $394K | May 13, 2026 | — |
| Thomas HaugheyDirector | — | $162K | Jun 10, 2026 | — |
| Renee P TannenbaumDirector | — | $146K | Dec 9, 2025 | — |
| Jeanne ThomaDirector | — | $72K | Sep 14, 2026 | — |
ANIP stock: common questions
Are ANI PHARMACEUTICALS INC insiders buying ANIP stock?
In the past 12 months, 0 insiders reported open-market purchases of ANIP worth $0.
Are ANI PHARMACEUTICALS INC insiders selling ANIP stock?
12 insiders reported sales worth $15.1M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ANIP's 52-week range?
Over the past year ANIP has traded between $70.19 and $95.38. It last closed at $73.89 on Oct 9, 2026.